Compare Amgen, Inc. (AMGN) vs Five Below Inc (FIVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Five Below Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Five Below Inc trades at $189.77 (market cap $10.47B). The key difference: Amgen, Inc. is far larger — about 18.7× Five Below Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Five Below Inc pays none. Which is the better fit depends on your goals.
| AMGN | FIVE | |
|---|---|---|
Market Cap | $196.12B | $10.47B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $247.71 |
52-Week Low | $271.18 | $129.46 |
Enterprise Value | $241.41B | $11.36B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
FIVE trades at $189.39, up 2.8% today, with a bearish technical signal but strong fundamentals including a 36.81% gross margin and 21.13% ROE. Recent earnings beats and a 60% analyst buy rating support momentum, while expansion to 2,000 stores (GlobeNewsWire, July 9, 2026) highlights growth. The stock faces resistance near $191 with net cash flow positive at $152 million in 2025.
Outlook remains positive with a $252.09 consensus target, though risks include margin pressure from 2025's 6.54% net margin and bearish moving averages. Growth drivers are digital marketing and store openings, but investor caution is warranted near technical resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
